Cerebral Amyloid-β Deposition, Axial Features, and Cognitive Alterations in Patients with Parkinson's Disease Treated with Bilateral STN-DBS: A Long-Term Cohort Study.

Our aim was to evaluate the possible long-term cerebral deposition of amyloid-β in patients with PD treated with subthalamic nucleus deep brain stimulation (STN-DBS) and its possible influence on axial and cognitive variables. Consecutive PD patients treated with bilateral STN-DBS with a long-term follow-up were included. The amyloid-β deposition was evaluated postoperatively through an 18F-flutemetamol positron emission tomography (PET) study.

On the Converse of Pansu's Theorem.

We provide a suitable generalisation of Pansu's differentiability theorem to general Radon measures on Carnot groups and we show that if Lipschitz maps between Carnot groups are Pansu-differentiable almost everywhere for some Radon measures , then must be absolutely continuous with respect to the Haar measure of the group.

Renal Disease in Cats and Dogs-Lessons Learned from Text-Mined Trends in Humans.

Chronic kidney disease (CKD) is characterised by progressive kidney damage and encompasses a broad range of renal pathologies and aetiologies. In humans, CKD is an increasing global health problem, in particular in the western world, while in cats and dogs, CKD is one of the leading causes of mortality and morbidity. Here, we aimed to develop an enhanced understanding of the knowledge base related to the pathophysiology of renal disease and CKD in cats and dogs.

Best Paper Award SIAMOC 2023: Use of Gait Profile Score and Gait Variable Score to quantify patient improvement immediately following neuro-orthopedic surgery in patients with cerebral palsy - A prospective cohort study.

Background: The Gait Profile Score (GPS) and the Gait Variable Score (GVS) are summary measures used to assess the long-term effects of neuro-orthopedic surgery (NOS) in children with cerebral palsy (cwCP).

Research Question: What are the immediate changes after NOS as assessed by GPS and GVS, and how does GPS variation (ΔGPS) compare to the clinical opinion of the NOS outcome?

Methods: Prospective single-arm cohort study. CwCP were assessed before NOS and after the first month of weight-bearing.

Experimental validation of a parenteral permitted daily exposure value for cleaning-induced degradants from recombinant therapeutic proteins with in vitro immunogenicity assays.

Multiproduct manufacturing of biotherapeutic proteins generate cleaning-induced protein degradants because of extreme pH and temperature conditions during the cleaning process. Cleaning Acceptance limits are calculated based on the maximum allowable carryover (MAC) assessment of the previously manufactured active pharmaceutical ingredient (API) - or drug product - based on the permitted daily exposure (PDE) of the previously manufactured API into the dose of subsequent product. In this study, we tested a previously determined PDE value for cleaning-induced protein degradants of 650 µg/dose.